The Alexandra General Hospital is a General hospital in central Athens, Greece. It was established in 1954, initially as a Maternity Hospital and later as a Maternity & Obstetrics - Gynecological Hospital. It is located at Vassilisis Sofias avenue in the center of Athens.

There are 350 beds in General Hospital of Athens Alexandra.

During the past decade, General Hospital of Athens Alexandra conducted 61 clinical trials. In the 10-year time frame, 61 clinical trials started and 24 clinical trials were completed, i.e. on average, 39.3% percent of trials that started reached the finish line to date. In the past 5 years, 28 clinical trials started and 16 clinical trials were completed. i.e. 57.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "General Hospital of Athens Alexandra" #1 sponsor was "Hoffmann-La Roche" with 18 trials, followed by "Hellenic Society of Hematology" with 6 trials sponsored, "Celgene" with 5 trials sponsored, "European Myeloma Network" with 4 trials sponsored and "Bayer" with 4 trials sponsored. Other sponsors include 35 different institutions and companies that sponsored additional 33 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "General Hospital of Athens Alexandra" #1 collaborator was "Sanofi" with 3 trials as a collaborator, "AstraZeneca" with 2 trials as a collaborator, "Daiichi Sankyo Co., Ltd." with 2 trials as a collaborator, "GlaxoSmithKline" with 2 trials as a collaborator and "Janssen Pharmaceuticals" with 2 trials as a collaborator. Other collaborators include 29 different institutions and companies that were collaborators in the rest 37 trials.

According to Clinical.Site data, the most researched conditions in "General Hospital of Athens Alexandra" are "Multiple Myeloma" (24 trials), "Breast Cancer" (6 trials), "Prostate Cancer" (3 trials), "Renal Impairment" (3 trials) and "Amyloidosis" (2 trials). Many other conditions were trialed in "General Hospital of Athens Alexandra" in a lesser frequency.

Most popular intervention types in "General Hospital of Athens Alexandra" are "Drug" (71 trials), "Other" (6 trials), "Biological" (1 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab" (10 trials), "Placebo" (10 trials), "Dexamethasone" (9 trials), "Paclitaxel" (6 trials) and "Bortezomib" (5 trials). Other intervention names were less common.

The vast majority of trials in "General Hospital of Athens Alexandra" are 63 trials for "All" genders, 8 trials for "Female" genders and 5 trials for "Male" genders.

Currently, there are 38 active trials in "General Hospital of Athens Alexandra". 2 are not yet recruiting, 15 are recruiting, 20 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 25 completed trials in General Hospital of Athens Alexandra, undefined suspended trials, and 8 terminated clinical trials to date.

Out of the total trials that were conducted in General Hospital of Athens Alexandra, 8 "Phase 1" clinical trials were conducted, 29 "Phase 2" clinical trials and 38 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".